Systemic lupus erythematosus-associated pulmonary hypertension: clinical variables and survival outcome

Ciang, Chu Oi; Chan, Pui Shan Julia; Leung, Moon Ho

doi:10.2217/ijr.15.15

Cited by 2 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it can be a stable predictor as it will not fluctuate along the disease activity, which is different from anti-dsDNA. Anti-Sm has a low positivity among SLE–PAH patients (15.8–41.4%), 8,34,40,41 which may be the reason why the association has not been found in small sample sizes.…”

Section: Discussionmentioning

confidence: 95%

Serological biomarkers as risk factors of SLE-associated pulmonary arterial hypertension: a systematic review and meta-analysis

Wang

Qian

Wang

et al. 2017

Lupus

View full text Add to dashboard Cite

Objective This article aims to determine the serological biomarkers which can be considered as risk factors of systemic lupus erythematosus (SLE)-associated pulmonary arterial hypertension by a systematic review and meta-analysis. Methods This study was conducted in accordance with the PRISMA statement. The search database included MEDLINE, EMBASE, Cochrane Library and Scopus. The Newcastle-Ottawa scale was used for the quality assessment. The odds ratio was the primary measure of effect of the risk factors. Results Twelve studies were included in this meta-analysis. The results identified the anti-RNP antibody and anti-Sm antibody as risk factors for SLE-associated pulmonary arterial hypertension with the pooled odds ratios 3.68 (95% confidence interval 2.04-6.63, P < 0.0001) and 1.71 (95% confidence interval 1.06-2.76, P = 0.03), respectively. Conclusion Pulmonary arterial hypertension is a serious complication of SLE with a worse prognosis than SLE patients without pulmonary arterial hypertension. The early recognition of pulmonary arterial hypertension with transthoracic echocardiography routinely performed in SLE patients with risk factors is necessary, especially in Asian patients.

show abstract

Section: Discussionmentioning

confidence: 95%

Serological biomarkers as risk factors of SLE-associated pulmonary arterial hypertension: a systematic review and meta-analysis

Wang

Qian

Wang

et al. 2017

Lupus

View full text Add to dashboard Cite

show abstract

“…There are several confounding factors which can cause PAH, such as interstitial lung disease, ischemic heart disease, valvular heart disease, cardiomyopathy and COPD, or PAH caused by other connective tissue disease. So, these were excluded from the study 7. In our population, due to the delayed presentation of disease, complicated cases are seen in clinics.…”

Section: Introductionmentioning

confidence: 99%

Frequency and predictors of pulmonary hypertension in patients with Systemic Lupus Erythematosus

et al. 2019

View full text Add to dashboard Cite

Objective: To determine the frequency and predictors of pulmonary hypertension in patients with Systemic Lupus Erythematosus in a Pakistani population, presenting at a tertiary care hospital Methods: This cross-sectional study was conducted at the Department of Rheumatology, Shiekh Zayed Hospital, Lahore from March to June 2018. A total of 97 patients, who fulfilled the Systemic Lupus Erythematosus (SLE) criteria of American College of Rheumatology (ACR) 1992 were enrolled. Pulmonary Arterial Hypertension (PAH) was measured by calculating pulmonary arterial systolic pressure through echocardiography by a single consultant cardiologist. Disease characteristics and demography was collected in a self-administered proforma. PAH was defined as mean pulmonary arterial pressure of 25mmHg or above by calculating with a formula. SPSS version 20 was used for analysis of data. Results: Out of 97 patients, 89.7% (n=87) were females and 10.3% (n=10) were males, with mean age of 31.29±8.824 years. The mean disease duration was 24.21±30.46 months. PAH was found in 23.3% (n=23) patients, including 19 females and 4 males. On further analysis of data, Raynaud phenomenon, rheumatoid factor and nephritis were assessed as predictors of PAH and all of these showed statistical significance for presence of PAH as per Chi-square test (p<0.05). Conclusion: In this study, 23.3% SLE patients showed evidence of PAH and positive statistical significance was found between predictors like Raynaud phenomenon, rheumatoid factor, nephritis and presence of PAH. So it is imperative to detect PAH early and start prompt treatment to achieve better quality of life. How to cite this:Asif S, Rasheed A, Mahmud TH, Asghar A. Frequency and predictors of pulmonary hypertension in patients with Systemic Lupus Erythematosus. Pak J Med Sci. 2019;35(1):86-89. doi: https://doi.org/10.12669/pjms.35.1.405 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Systemic lupus erythematosus-associated pulmonary hypertension: clinical variables and survival outcome

Cited by 2 publications

References 35 publications

Serological biomarkers as risk factors of SLE-associated pulmonary arterial hypertension: a systematic review and meta-analysis

Serological biomarkers as risk factors of SLE-associated pulmonary arterial hypertension: a systematic review and meta-analysis

Frequency and predictors of pulmonary hypertension in patients with Systemic Lupus Erythematosus

Contact Info

Product

Resources

About